SCHEMBL427749

SCHEMBL427749

O=C(N1CCC2(CC1)OCCO2)n1cnc(-c2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.56
RAB9A P51151 5/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
MAPT P10636 2/20 0.56
GAA P10253 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
ALDH1A1 P00352 6/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KDM4E B2RXH2 1/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
ALPL P05186 1/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424563 0.83 NPC1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL12781917 0.69 KMO (0.44) NPC1RAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL3004092 0.68 CNR2 (0.46) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL425673 0.68 POLB (0.51) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL426612 0.67 ALDH1A1 (0.51) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL424650 0.66 MAP4K4 (0.39) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL16102528 0.64 ALDH1A1 (0.50) NPC1RAB9ASMN1; SMN2MAPTGAA
SCHEMBL4540057 0.63 CYP2E1 (0.49) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL427487 0.63 MAP4K4 (0.36) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL424568 0.63 HSP90AA1 (0.54) SMN1; SMN2MAPTLMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 NPC1 446/4885RAB9A 2266/4885SMN1; SMN2 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.